Using TipRanks’ popular Insiders’ Hot Stocks tool, we found which stocks best-performing corporate insiders like right now. We differentiate between informative and uninformative insider transactions in order to find the most compelling opportunities.

Uninformative transactions indicate that an insider is buying/selling shares for reasons that do not necessarily indicate confidence in the company, such as exercising share options. In contrast, informative transactions are deliberately made by insiders, often because they feel the stock is undervalued.

In this case, we looked at stocks that exhibit strong buy indicators based on informative transactions of top insiders who are company executives, board members or 10 percent shareholders of publicly traded companies. We also used all four insider trading strategies:

So now let’s check out the three soaring stocks that are seeing particularly interesting insider buying right now:

MyoKardia Inc (MYOK)

On August 16, Sanofi snapped up 350,000 shares in MyoKardia (NASDAQ: MYOK) worth about $12,425,000. >10% owner Sanofi’s total Myokandia shareholding now stands at about $187 million.

Shares in MyoKardia have spiked 242% in the last three months from $13 to $44. Prices rose on MyoKardia’s groundbreaking heart disease study for its Mavacamten lead drug candidate. “Going from NYHA Class III to Class I is really impressive from the point of view of patient symptoms…going from fatigue with mild exertion to being completely asymptomatic,” said Marc Semigran, CMO of MyoKardia.

As a result of the data, and the efficacy on peak VO2 [maximum oxygen consumption], MyoKardia is now planning to meet with the FDA and bypass a Phase IIb trial. Going straight to a registration study could cut as much as 18 months out of the development timeline. The stock has a Strong Buy analyst consensus rating with a $56 average analyst price target (27% upside).

And Sanofi, a French pharma giant, is a top insider to track. TipRanks shows that Sanofi has a five-star rating on TipRanks and a ranking of #96 out of 38,529 insiders. It's biggest holding- worth about $11.5 billion- is in biotech Regeneron but the company also has sizeable positions in Regulus and Alnylam Pharma.

BeiGene Ltd (BGNE)

Chinese biopharma BeiGene (NASDAQ: BGNE) is focused on ‘discovering the next-generation of cancer treatments.’ On August 14, Baker Bros Advisors made a purchase of $12.5 million shares in BGNE. Baker Bros now has a total of $7 billion of shares in BeiGene.

In the last three months, we can see that prices have exploded from just $38 to $69- a leap of 83%. At the beginning of July global biopharma Celgene (CELG) snapped up the ex-Asia rights to BeiGene’s PD-1 inhibitor BGB-A317 in solid tumors for $263 million. Baird analyst Brian Skorney raised his BGNE described the terms of the company’s deal with Celgene as “shockingly good.” He points out that Celgene is a “deep-pocketed partner” that may well pay a sizable portion of the $980 million in milestones despite the competitive environment for PD-1 inhibitors.

Director and >10% owner Baker Bros has a five-star rating on TipRanks. The company, which has total insider holdings of $8 billion, is ranked #185 out of 38,529 insiders. This breaks down into a 50% success rate and 26.3% average return.

Intrepid Potash (IPI)

In the last month, insiders have made 10 consecutive purchases of shares in Intrepid Potash (NYSE: IPI). Two of these transactions came in at over $1.5 million of shares each. For example, >10% owner Clearway Capital Management bought shares worth $55,000 on August 22- taking the company’s total IPI holding to $46 million.

Intrepid Potash is the largest producer of potassium chloride, also known as muriate of potash, in the US. The company has three solar solution facilities in Moab and Wendover, Utah and Carlsbad, New Mexico- see the photo of potash evaporation ponds in Utah above.

In the last three months, momentum has pushed shares in IPI up by over 40% from $2.30 to $3.42. However the company still has an uphill battle ahead due to the difficult fertilizer environment, hence a Hold analyst consensus rating on TipRanks.